Development of Dl1.72, a Novel Anti-DLL1 Antibody with Anti-Tumor Efficacy against Estrogen Receptor-Positive Breast Cancer

The Notch-signaling ligand DLL1 has emerged as an important player and promising therapeutic target in breast cancer (BC). DLL1-induced Notch activation promotes tumor cell proliferation, survival, migration, angiogenesis and BC stem cell maintenance. In BC, DLL1 overexpression is associated with po...

Full description

Bibliographic Details
Main Author: Silva, G (author)
Other Authors: Sales-Dias, J (author), Casal, D (author), Alves, S (author), Domenici, G (author), Barreto, C (author), Matos, C (author), Lemos, A (author), Matias, A (author), Kucheryava, K (author), Ferreira, A (author), Moita, MR (author), Braga, S (author), Brito, C (author), Cabral, MG (author), Casalou, C (author), Barral, D (author), Sousa, P (author), Videira, P (author), Bandeiras, T (author), Barbas, A (author)
Format: article
Language:eng
Published: 2021
Subjects:
HSJ ANPAT
DLL1
ER+ Breast Cancer
Notch Signaling
Angiogenesis
Cell Proliferation
Monoclonal Antibody
Tumor Growth.
Online Access:http://hdl.handle.net/10400.17/3881
Country:Portugal
Oai:oai:repositorio.chlc.min-saude.pt:10400.17/3881

Internet

http://hdl.handle.net/10400.17/3881

Similar Items